No impact of Covid-19 vaccine trial on stocks
The world economy is optimistic about the success of these vaccines; Bangladesh’s stock markets, however, have not shown such optimism
There is no impact of Covid-19 vaccine trial on the country's stock markets while most of the stock exchanges in the world saw a significant rise following Covid-19 vaccine breakthrough from US and German drug makers Pfizer and BioNTech.
Recently, the vaccine's trials have shown that it is more than 90% effective in preventing the novel coronavirus infection, much higher than expected.
The world economy is optimistic about the success of these vaccines; however, Bangladesh's stock markets have not shown such optimism.
On Tuesday, DSEX, the key index of the Dhaka Stock Exchange (DSE), fell by 0.57%, or 28.43 points to 4,899. However, the turnover of the DSE rose by 5% to Tk925.11 crore.
The prime index CASPI of port city bourse Chittagong Stock Exchange (CSE) also lost 0.38%, or 53.75 points to 14,065.
EBL Securities in its daily market review said many investors did not put money to the stock markets for forthcoming IPO offers as a side-line strategy, as several giant corporations are set to be listed on the capital market.
Meanwhile, the mutual fund has generated the highest return by 4.2%, while eight funds secured a place in the top 10 gainer table at the DSE.
However, Eastern Bank announced to sell 4.55 crore units of three mutual funds. The bank is a sponsor of these funds.
The financial institution was the worst performer in sectoral return. This sector lost 3.8% of market capital on Tuesday.
Besides, Associated Oxygen was the looser share in the top ten looser list at the DSE. The company's share price fell by 9.39% to Tk55 per share, after the securities regulator formed a committee on Monday to investigate recent unusual price hike of the company.